BIO Notebook, Day 2: Deal Insights, A Payer Perspective And EMA Rumors
In the spirit of the BIO International Convention's partnering focus, Scrip covered a dealmaker survey and spoke to Bayer about some of its business development priorities on day two of the annual convention. We also report on a payer perspective, post-Brexit EMA rumors and investments in vaccines.
You may also be interested in...
Companies with market caps below $1bn continue to represent a growing percentage of biopharma deal-making, giving firms looking to license or partner assets increased optionality, Inventiv Health's Neel Patel told a session at BIO 2017.
The first gene therapy approval could be coming soon – followed shortly by the first ever gene therapy coverage decision. An Express Scripts executive argues that the tone may be affected by the initial indication.
At $19,500 per year, Radius Health's Tymlos (abaloparatide) is priced to compete with Lilly's similar, but well-established drug Forteo. The company hopes to increase the size of the osteoporosis market to achieve its blockbuster sales goal, but at least one analyst has her doubts.